

# SAFETY DATA SHEET



## Montelukast Tablet Formulation



Version 2.15      Revision Date: 02.10.2020      SDS Number: 23079-00017      Date of last issue: 23.03.2020  
Date of first issue: 17.10.2014

---

### 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Montelukast Tablet Formulation

#### Manufacturer or supplier's details

Company : Organon & Co.

Address : 30 Hudson Street, 33rd floor  
Jersey City, New Jersey, U.S.A 07302

Telephone : 551-430-6000

Emergency telephone number : 215-631-6999

E-mail address : EHSSTEWARD@organon.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

---

### 2. HAZARDS IDENTIFICATION

#### Manufacture, Storage and Import of Hazardous Chemicals Rules 1989

##### Classification

Not classified as hazardous according to criteria laid down in Part I of Schedule-1.

##### GHS Classification

Not a hazardous substance or mixture.

##### GHS label elements

Not a hazardous substance or mixture.

##### Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.  
Contact with dust can cause mechanical irritation or drying of the skin.  
May form explosive dust-air mixture during processing, handling or other means.

---

### 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

#### Components

Chemical name	CAS-No.	Concentration (% w/w)
Cellulose	9004-34-6	$\geq 30 - < 50$
Montelukast	151767-02-1	$\geq 5 - < 10$
Magnesium stearate	557-04-0	$\geq 1 - < 5$
Titanium dioxide	13463-67-7	$\geq 0.1 - < 1$

---

### 4. FIRST AID MEASURES

# SAFETY DATA SHEET



## Montelukast Tablet Formulation



Version 2.15      Revision Date: 02.10.2020      SDS Number: 23079-00017      Date of last issue: 23.03.2020  
Date of first issue: 17.10.2014

---

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention.
- In case of skin contact : Wash with water and soap.  
Get medical attention if symptoms occur.
- In case of eye contact : If in eyes, rinse well with water.  
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention if symptoms occur.  
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : Contact with dust can cause mechanical irritation or drying of the skin.  
Dust contact with the eyes can lead to mechanical irritation.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.
- 

### 5. FIREFIGHTING MEASURES

- Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.  
Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides  
Metal oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.
- Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.
- 

### 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.

## Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
2.15	02.10.2020	23079-00017	Date of first issue: 17.10.2014

Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

**7. HANDLING AND STORAGE**

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe dust.  
Do not swallow.  
Avoid contact with eyes.  
Avoid prolonged or repeated contact with skin.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Minimize dust generation and accumulation.  
Keep container closed when not in use.  
Keep away from heat and sources of ignition.  
Take precautionary measures against static discharges.  
Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage : Keep in properly labelled containers.  
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents

**8. EXPOSURE CONTROLS/PERSONAL PROTECTION****Components with workplace control parameters**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	TWA	10 mg/m <sup>3</sup>	ACGIH
Montelukast	151767-02-1	TWA	40 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	400 µg/100 cm <sup>2</sup>	Internal

# SAFETY DATA SHEET



## Montelukast Tablet Formulation



Version 2.15      Revision Date: 02.10.2020      SDS Number: 23079-00017      Date of last issue: 23.03.2020  
Date of first issue: 17.10.2014

Magnesium stearate	557-04-0	TWA (Inhalable particulate matter)	10 mg/m <sup>3</sup>	ACGIH
		TWA (Respirable particulate matter)	3 mg/m <sup>3</sup>	ACGIH
Titanium dioxide	13463-67-7	TWA	10 mg/m <sup>3</sup> (Titanium dioxide)	ACGIH

**Engineering measures** : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).  
Minimize open handling.

### Personal protective equipment

**Respiratory protection** : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

**Filter type** : Particulates type

**Hand protection**

**Material** : Chemical-resistant gloves

**Remarks** : Consider double gloving.

**Eye protection** : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin and body protection** : Work uniform or laboratory coat.  
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.  
Use appropriate degowning techniques to remove potentially contaminated clothing.

**Hygiene measures** : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

## 9. PHYSICAL AND CHEMICAL PROPERTIES

**Appearance** : tablet

# SAFETY DATA SHEET



## Montelukast Tablet Formulation



Version 2.15      Revision Date: 02.10.2020      SDS Number: 23079-00017      Date of last issue: 23.03.2020  
Date of first issue: 17.10.2014

---

Colour : coloured

Odour : odourless

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : Not applicable

Evaporation rate : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)  
Water solubility : No data available

Partition coefficient: n-octanol/water : No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity  
Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

## Montelukast Tablet Formulation

Version 2.15      Revision Date: 02.10.2020      SDS Number: 23079-00017      Date of last issue: 23.03.2020  
Date of first issue: 17.10.2014

---

Particle size : No data available

---

**10. STABILITY AND REACTIVITY**

Reactivity : Not classified as a reactivity hazard.  
Chemical stability : Stable under normal conditions.  
Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.  
Can react with strong oxidizing agents.  
Conditions to avoid : Heat, flames and sparks.  
Avoid dust formation.  
Incompatible materials : Oxidizing agents  
Hazardous decomposition products : No hazardous decomposition products are known.

---

**11. TOXICOLOGICAL INFORMATION**

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

**Acute toxicity**

Not classified based on available information.

**Components:****Cellulose:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg  
Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

**Montelukast:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg  
LD50 (Mouse): > 5,000 mg/kg  
Acute inhalation toxicity : Remarks: No data available  
Acute dermal toxicity : Remarks: No data available

**Magnesium stearate:**

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 423  
Assessment: The substance or mixture has no acute oral toxicity  
Remarks: Based on data from similar materials

---

## Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
2.15	02.10.2020	23079-00017	Date of first issue: 17.10.2014

---

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg  
Remarks: Based on data from similar materials

**Titanium dioxide:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 6.82 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Assessment: The substance or mixture has no acute inhalation toxicity

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****Montelukast:**

Species : Rabbit  
Result : Mild skin irritation

**Magnesium stearate:**

Species : Rabbit  
Result : No skin irritation  
Remarks : Based on data from similar materials

**Titanium dioxide:**

Species : Rabbit  
Result : No skin irritation

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:****Montelukast:**

Species : Rabbit  
Result : Severe irritation

**Magnesium stearate:**

Species : Rabbit  
Result : No eye irritation  
Remarks : Based on data from similar materials

**Titanium dioxide:**

Species : Rabbit  
Result : No eye irritation

## Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
2.15	02.10.2020	23079-00017	Date of first issue: 17.10.2014

---

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.

**Components:****Montelukast:**

Remarks : No data available

**Magnesium stearate:**

Test Type : Maximisation Test  
 Exposure routes : Skin contact  
 Species : Guinea pig  
 Method : OECD Test Guideline 406  
 Result : negative  
 Remarks : Based on data from similar materials

**Titanium dioxide:**

Test Type : Local lymph node assay (LLNA)  
 Exposure routes : Skin contact  
 Species : Mouse  
 Result : negative

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****Cellulose:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
 Result: negative  
 Test Type: In vitro mammalian cell gene mutation test  
 Result: negative  
 Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo  
 cytogenetic assay)  
 Species: Mouse  
 Application Route: Ingestion  
 Result: negative

**Montelukast:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
 Result: negative  
 Test Type: In vitro mammalian cell gene mutation test  
 Test system: Chinese hamster fibroblasts  
 Result: negative



## Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
2.15	02.10.2020	23079-00017	Date of first issue: 17.10.2014

---

Test Type: Chromosomal aberration  
 Test system: Chinese hamster ovary cells  
 Result: negative

Test Type: Alkaline elution assay  
 Test system: rat hepatocytes  
 Result: negative

Genotoxicity in vivo : Test Type: Chromosomal aberration  
 Species: Mouse  
 Cell type: Bone marrow  
 Application Route: Oral  
 Result: negative

**Magnesium stearate:**

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test  
 Result: negative  
 Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro  
 Method: OECD Test Guideline 473  
 Result: negative  
 Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)  
 Result: negative  
 Remarks: Based on data from similar materials

**Titanium dioxide:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
 Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test  
 Species: Mouse  
 Result: negative

**Carcinogenicity**

Not classified based on available information.

**Components:****Cellulose:**

Species : Rat  
 Application Route : Ingestion  
 Exposure time : 72 weeks  
 Result : negative

**Montelukast:**

Species : Rat  
 Application Route : Oral  
 Exposure time : 2 Years  
 Result : negative

## Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
2.15	02.10.2020	23079-00017	Date of first issue: 17.10.2014

---

Species : Mouse  
 Application Route : Oral  
 Exposure time : 92 weeks  
 Result : negative

**Titanium dioxide:**

Species : Rat  
 Application Route : inhalation (dust/mist/fume)  
 Exposure time : 2 Years  
 Method : OECD Test Guideline 453  
 Result : positive  
 Remarks : The mechanism or mode of action may not be relevant in humans.

Carcinogenicity - Assessment : Limited evidence of carcinogenicity in inhalation studies with animals.

**Reproductive toxicity**

Not classified based on available information.

**Components:****Cellulose:**

Effects on fertility : Test Type: One-generation reproduction toxicity study  
 Species: Rat  
 Application Route: Ingestion  
 Result: negative

Effects on foetal development : Test Type: Fertility/early embryonic development  
 Species: Rat  
 Application Route: Ingestion  
 Result: negative

**Montelukast:**

Effects on fertility : Test Type: Fertility  
 Species: Rat, male  
 Application Route: Oral  
 Fertility: NOAEL: 800 mg/kg body weight  
 Result: Animal testing did not show any effects on fertility.

Test Type: Fertility  
 Species: Rat, female  
 Application Route: Oral  
 Fertility: LOAEL: 200 mg/kg body weight  
 Symptoms: Reduced fertility

Test Type: Fertility  
 Species: Rat, female  
 Application Route: Oral  
 Fertility: NOAEL: 100 mg/kg body weight  
 Symptoms: Reduced fertility

## Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
2.15	02.10.2020	23079-00017	Date of first issue: 17.10.2014

---

**Magnesium stearate:**

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test  
Species: Rat  
Application Route: Ingestion  
Method: OECD Test Guideline 422  
Result: negative  
Remarks: Based on data from similar materials

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Ingestion  
Result: negative  
Remarks: Based on data from similar materials

**STOT - single exposure**

Not classified based on available information.

**STOT - repeated exposure**

Not classified based on available information.

**Repeated dose toxicity****Components:****Cellulose:**

Species : Rat  
NOAEL :  $\geq 9,000$  mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days

**Montelukast:**

Species : Monkey, male and female  
NOAEL : 150 - 300 mg/kg  
Application Route : Oral  
Exposure time : 53 Weeks  
Remarks : No significant adverse effects were reported

Species : Rat  
NOAEL : 50 mg/kg  
Application Route : Oral  
Exposure time : 53 Weeks  
Remarks : No significant adverse effects were reported

Species : Mouse  
NOAEL : 50 mg/kg  
Application Route : Oral  
Exposure time : 14 Weeks  
Remarks : No significant adverse effects were reported

**Magnesium stearate:**

Species : Rat

## Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
2.15	02.10.2020	23079-00017	Date of first issue: 17.10.2014

---

NOAEL : > 100 mg/kg  
 Application Route : Ingestion  
 Exposure time : 90 Days  
 Remarks : Based on data from similar materials

**Titanium dioxide:**

Species : Rat  
 NOAEL : 24,000 mg/kg  
 Application Route : Ingestion  
 Exposure time : 28 Days

Species : Rat  
 NOAEL : 10 mg/m<sup>3</sup>  
 Application Route : inhalation (dust/mist/fume)  
 Exposure time : 2 yr

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****Montelukast:**

Skin contact : Remarks: May irritate skin.  
 Eye contact : Symptoms: Severe irritation  
 Ingestion : Symptoms: upper respiratory tract infection, pharyngitis,  
 Headache, Cough, Abdominal pain, Diarrhoea, Fever

---

**12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****Cellulose:**

Toxicity to fish : LC50 (*Oryzias latipes* (Japanese medaka)): > 100 mg/l  
 Exposure time: 48 h  
 Remarks: Based on data from similar materials

**Montelukast:**

Toxicity to fish : LC50 (*Pimephales promelas* (fathead minnow)): > 0.0778 mg/l  
 Exposure time: 96 h  
 Method: OECD Test Guideline 203  
 Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates : EC50 (*Daphnia magna* (Water flea)): > 0.0675 mg/l  
 Exposure time: 48 h  
 Method: OECD Test Guideline 202  
 Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic plants : NOEC (*Pseudokirchneriella subcapitata* (green algae)): 100 mg/l

## Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
2.15	02.10.2020	23079-00017	Date of first issue: 17.10.2014

---

Exposure time: 72 h  
Method: OECD Test Guideline 201  
Remarks: No toxicity at the limit of solubility

EC50 ( Pseudokirchneriella subcapitata (green algae)): > 100 mg/l

Exposure time: 72 h  
Method: OECD Test Guideline 201  
Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms : EC50: > 100 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209  
Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic toxicity) : NOEC: 0.073 mg/l  
Exposure time: 32 d  
Species: Pimephales promelas (fathead minnow)  
Method: OECD Test Guideline 210  
Remarks: No toxicity at the limit of solubility

NOEC: 0.0816 mg/l  
Exposure time: 7 d  
Species: Cyprinodon variegatus (sheepshead minnow)  
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 0.23 mg/l  
Exposure time: 21 d  
Species: Daphnia magna (Water flea)  
Remarks: No toxicity at the limit of solubility

**Magnesium stearate:**

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l  
Exposure time: 48 h  
Method: DIN 38412  
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 1 mg/l  
Exposure time: 47 h  
Test substance: Water Accommodated Fraction  
Method: Directive 67/548/EEC, Annex V, C.2.  
Remarks: Based on data from similar materials  
No toxicity at the limit of solubility

Toxicity to algae/aquatic plants : EL50 ( Pseudokirchneriella subcapitata (green algae)): > 1 mg/l  
Exposure time: 72 h  
Test substance: Water Accommodated Fraction  
Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials  
No toxicity at the limit of solubility

NOELR ( Pseudokirchneriella subcapitata (green algae)): > 1

## Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
2.15	02.10.2020	23079-00017	Date of first issue: 17.10.2014

---

mg/l  
 Exposure time: 72 h  
 Test substance: Water Accommodated Fraction  
 Method: OECD Test Guideline 201  
 Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l  
 Exposure time: 16 h  
 Test substance: Water Accommodated Fraction  
 Remarks: Based on data from similar materials

**Titanium dioxide:**

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l  
 Exposure time: 96 h  
 Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l  
 Exposure time: 48 h

Toxicity to algae/aquatic plants : EC50 ( Skeletonema costatum (marine diatom)): > 10,000 mg/l  
 Exposure time: 72 h

Toxicity to microorganisms : EC50: > 1,000 mg/l  
 Exposure time: 3 h  
 Method: OECD Test Guideline 209

**Persistence and degradability****Components:****Cellulose:**

Biodegradability : Result: Readily biodegradable.

**Montelukast:**

Biodegradability : Result: not rapidly degradable  
 Biodegradation: 0 %  
 Exposure time: 28 d

Stability in water : Hydrolysis: 50 %(21.7 h)

**Magnesium stearate:**

Biodegradability : Result: Not biodegradable  
 Remarks: Based on data from similar materials

**Bioaccumulative potential****Components:****Montelukast:**

Partition coefficient: n-octanol/water : log Pow: > 4.3

# SAFETY DATA SHEET



## Montelukast Tablet Formulation



Version 2.15      Revision Date: 02.10.2020      SDS Number: 23079-00017      Date of last issue: 23.03.2020  
Date of first issue: 17.10.2014

---

### Magnesium stearate:

Partition coefficient: n-octanol/water : log Pow: > 4

### Mobility in soil

No data available

### Other adverse effects

No data available

---

## 13. DISPOSAL CONSIDERATIONS

### Disposal methods

Waste from residues : Dispose of in accordance with local regulations.  
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

## 14. TRANSPORT INFORMATION

### International Regulations

#### UNRTDG

Not regulated as a dangerous good

#### IATA-DGR

Not regulated as a dangerous good

#### IMDG-Code

Not regulated as a dangerous good

### Transport in bulk according to IMO instruments

Not applicable for product as supplied.

---

## 15. REGULATORY INFORMATION

**Safety, health and environmental regulations/legislation specific for the substance or mixture**

**The components of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

IECSC : not determined

---

## 16. OTHER INFORMATION

### Further information

Sources of key data used to : Internal technical data, data from raw material SDSs, OECD

---

## Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
2.15	02.10.2020	23079-00017	Date of first issue: 17.10.2014

compile the Safety Data Sheet : eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : dd.mm.yyyy

**Full text of other abbreviations**

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECl - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IN / EN